MedTrace Logo

The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery

NCT06087237 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-06-26

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the efficacy of pentoxifylline in reducing postsurgical complications for breast cancer patients undergoing breast cancer surgery. It aims to evaluate the efficacy of pentoxifylline on postoperative pain and wound healing.

Conditions

  • Post-Surgical Complication
  • Breast Cancer Surgery

Interventions

DRUG

Pentoxifylline

Two 400 mg extended-release pentoxifylline oral tablets are administered 2 hours before surgery, then one tablet three times per day after surgery, and continued for four weeks after the surgery. Standard of care for pain management, including paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours.

DRUG

paracetamol +ketorolac

Patients receive the usual treatment only: paracetamol 1g IV every 8 hours and Ketorolac 30 mg IV every 12 hours

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Samar A. Dewidar, MSc · clinical pharmacy and pharmacy practice department, Faculty of pharmacy, Mansoura University

  • Noha O. Mansour, PhD · Clinical pharmacy and pharmacy practice department, Faculty of pharmacy, Mansoura University

  • Moetaza M. Soliman, PhD · Clinical pharmacy and pharmacy practice department, Faculty of pharmacy, Mansoura University

  • Mohamed A. Shams, PhD · Clinical pharmacy and pharmacy practice department, Faculty of pharmacy, Mansoura University

  • Omar H. Abdelaleem, PhD · Faculty pf medicine, Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-30
Primary Completion
2024-06-30
Completion
2024-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06087237 on ClinicalTrials.gov